Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 17 art units • 18 examiners • 0 of 20 (0%) have an AI response strategy ready • 29 patents granted in the last 365 days
Translate Bio Inc. has 22 pending office actions in Biotechnology & Pharmaceuticals. The matters span 20 distinct examiners and 18 distinct art units, indicating a broad and highly distributed examination footprint. The portfolio requires consistent internal tracking across numerous examiner relationships and art-unit procedures.
POPA, ILEANA is the busiest examiner, with 2 pending matters. That assignment is the clearest point of examiner concentration in the available data, but the wider distribution means counsel should not treat it as the sole prosecution priority.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (10%) |
| §103 only | 5 (25%) |
| §112 only | 2 (10%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 2 (10%) |
| Multi-statute (no §101) | 7 (35%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 2 | 21.7% | +15.7% |
| MOORE, JOHN DAVID | 2 | 61.1% | +28.3% |
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555439 | "Good" buffer-based cationic lipids | SHOMER, ISAAC | 9d |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 17534956 | Stable Liquid Lipid Nanoparticle Formulations | MITCHELL, EDWIN COLEMAN | 47d |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | RONEY, CELESTE A | — |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | — |
| 18552165 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | MOORE, JOHN DAVID | — |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555439 | "Good" buffer-based cationic lipids | SHOMER, ISAAC | 9d |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 9d |
| 18910694 | STABLE COMPOSITIONS OF MRNA-LOADED LIPID NANOPARTICLES AND PROCESSES OF MAKING | CABRAL, ROBERT S | — |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18815955 | Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle | JONES, DAMERON LEVEST | — |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | RONEY, CELESTE A | — |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | — |
| 18557446 | METHODS FOR MEASURING POLY A TAIL LENGTH | HANEY, AMANDA MARIE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1612 | 2 |
| 1638 | 2 |
| 1614 | 1 |
| 1618 | 1 |
| 1684 | 1 |
| 1693 | 1 |
| 1637 | 1 |
| 1632 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18910694 | STABLE COMPOSITIONS OF MRNA-LOADED LIPID NANOPARTICLES AND PROCESSES OF MAKING | CABRAL, ROBERT S | 1614 | Other | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | 1633 | §101§103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18815955 | Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle | JONES, DAMERON LEVEST | 1618 | DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18782767 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | RONEY, CELESTE A | 1612 | §103§112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18580463 | SCREENING CODON-OPTIMIZED NUCLEOTIDE SEQUENCES | GROSS, CHRISTOPHER M | 1684 | §102§103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18557446 | METHODS FOR MEASURING POLY A TAIL LENGTH | HANEY, AMANDA MARIE | 1693 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18555439 | "Good" buffer-based cationic lipids | SHOMER, ISAAC | 1612 | §102§112Other | Non-Final OA | 9d | Pending | Oct 13, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | ZARA, JANE J | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18552165 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | MOORE, JOHN DAVID | 1638 | §103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18065952 | LARGE-SCALE SYNTHESIS OF MESSENGER RNA | POHNERT, STEVEN C | 1683 | §103§112DP | Final Rejection | — | Pending | Dec 14, 2022 |
| 17923844 | GENERATION OF OPTIMIZED NUCLEOTIDE SEQUENCES | AUGER, NOAH ANDREW | 1687 | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 07, 2022 |
| 17800157 | IMPROVED PROCESSES FOR IN VITRO TRANSCRIPTION OF MESSENGER RNA | YAMASAKI, ROBERT J | 1657 | §102§103§112Other | Non-Final OA | — | Pending | Aug 16, 2022 |
| 17786971 | RECTAL DELIVERY OF MESSENGER RNA | KAMM, JUDITH MARIE | 1611 | §103 | Non-Final OA | — | Pending | Jun 17, 2022 |
| 17631322 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | CONNORS, ALEXANDRA F | 1634 | §112Other | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17539659 | ENCAPSULATION OF MESSENGER RNA | MOORE, JOHN DAVID | 1638 | §112Other | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17534956 | Stable Liquid Lipid Nanoparticle Formulations | MITCHELL, EDWIN COLEMAN | 1619 | §103§112Other | Non-Final OA | 47d | Pending | Nov 24, 2021 |
| 17450629 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | POPA, ILEANA | 1633 | §103Other | Non-Final OA | 9d | Pending | Oct 12, 2021 |
| 17472622 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | KIM, TAEYOON | 1631 | §103 | Final Rejection | — | Pending | Sep 11, 2021 |
| 17055251 | Subcutaneous Delivery of Messenger RNA | ARIETI, RUTH SOPHIA | 1635 | §103Other | Non-Final OA | 5d | Pending | Nov 13, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTranslate Bio Inc. has 20 pending office actions as of October 2026, spread across 17 art units and 18 examiners.
Ileana Popa has the most, with 2 of Translate Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
